A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Micro-Abstract Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within 6 months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease relapsed during or within 6 months after completion of platinum-based...

Full description

Saved in:
Bibliographic Details
Published inClinical ovarian & other gynecologic cancer Vol. 5; no. 2; pp. 53 - 59
Main Authors Smit, Willem M, Šufliarsky, Jozef, Werner, Theresa L, Dizon, Don S, Wagnerová, Maria, Hirte, Holger W, Spirtos, Nick M, Oza, Amit, Dirix, Luc, El-Hashimy, Mona, Acharyya, Suddhasatta, Tan, Eugene Y, Weber, Dirk, Schellens, Jan H.M
Format Journal Article
LanguageEnglish
Published 01.12.2012
Subjects
Hematology, Oncology and Palliative Medicine
Obstetrics and Gynecology
Platinum resistant
EPO906
Patupilone
Ovarian cancer
Platinum refractory
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract Effective treatment options for patients with ovarian cancer whose disease relapses or progresses within 6 months of initial therapy are limited. In the current open-label phase II study, 112 patients whose disease relapsed during or within 6 months after completion of platinum-based therapy received the novel microtubule-targeting agent patupilone. Patupilone was well tolerated and demonstrated promising efficacy in this difficult-to-treat population.
ISSN:2212-9553
2212-9561
DOI:10.1016/j.cogc.2012.06.001